PYRAPREG
Malaria in pregnant is a public health problem in sub Saharan countries where 11 million pregnancies are exposed to malaria infection. Plasmodium falciparum in pregnant can cause adverse maternal health and poor birth outcomes. Artemisin-based Combination Therapy (ACT) used in treatment of uncomplicated Plasmodium falciparum malaria in pregnant women has the efficacy in Africa. The malaria parasite has shown resistance to Sulfadoxine-Pyrimethamin (SP) used in intermittent preventive treatment (IPTp). Other ACT as Dihydroartemisinin-Piperaquine (DP) is a potential candidate to replace SP in IPTp. Deployment of DP as IPTp would limit significantly its use as curative treatment. There is the need of other ACT to increase therapeutic options for malaria treatment in 2nd and 3rd trimester. Pyronaridine – Artesunate (PA) can be is a potential candidate.
